Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).

Bone Marrow Transplant 2019 Nov 15;54(11):1868-1880. Epub 2019 May 15.

Division of Hematology, Ohio State University Wexner Medical Center, Columbus, OH, USA.

On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0451-2
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0451-2DOI Listing
November 2019
18 Reads

Publication Analysis

Top Keywords

blood marrow
16
society blood
12
marrow transplantation
12
acute lymphoblastic
8
transplantation ebmt
8
lymphoblastic leukemia
8
b-cell acute
8
chimeric antigen
8
american society
8
car-t
6
program safe
4
implementation car-t
4
anti cd19
4
ranging implementation
4
toxicity monitoring
4
car-t program
4
transplant physicians
4
drug long-term
4
physicians clinical
4
delivery drug
4

Altmetric Statistics

References

(Supplied by CrossRef)

CH June et al.
N Engl J Med 2018

SL Maude et al.
N Engl J Med 2018

MV Maus et al.
J Immunother Cancer 2017

E Mejstrikova et al.
Blood Cancer J 2017

JH Park et al.
N Engl J Med 2018

DW Lee et al.
Lancet 2015

J Duell et al.
Leukemia 2017

HM Kantarjian et al.
N Engl J Med 2016

RA Gardner et al.
Blood 2017

Similar Publications